Sodium Chloride 0.9% Injection shortage
To Be Discontinued 3 presentations · 1 manufacturers · first FDA posting 2025-12-03 · last update 2025-12-03
Manufacturers: Hospira, Inc., a Pfizer Company
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Sodium Chloride 0.9%, Injection, 250 mL ADD-Vantage® Flexible Container (NDC 0409-7101-02) | Hospira, Inc., a Pfizer Company | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 12/03/2025 Updated 12/03/2025 Discontinued 12/03/2025 |
| Sodium Chloride 0.9%, Injection, 50 mL ADD-Vantage® Flexible Container (NDC 0409-7101-66) | Hospira, Inc., a Pfizer Company | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 12/03/2025 Updated 12/03/2025 Discontinued 12/03/2025 |
| Sodium Chloride 0.9%, Injection, 100 mL ADD-Vantage® Flexible Container (NDC 0409-7101-67) | Hospira, Inc., a Pfizer Company | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 12/03/2025 Updated 12/03/2025 Discontinued 12/03/2025 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)